| 25th week of 2012 patent applcation highlights part 58 |
| Patent application number | Title | Published |
|---|
| 20120157349 | CELL CHIP PACKAGE - There is provided a cell chip package, including: a chamber having an opening formed in a region thereof; a cell chip received in an inside of the chamber and having a biomaterial array formed therein; and a sealing membrane mounted in the opening and made of a gas permeable material. The cell chip package may facilitate experimentation and long-term storage with respect to a cell chip. | 2012-06-21 |
| 20120157350 | Brownian Microbarcodes for Bioassays - Presented are encoded microparticles, methods of use in biological assays, and flexible, modular instrument systems for conducting a variety of biological assays using the encoded microparticles. The systems include various instrumentation components which are exchangeable and offer a single flexible platform on which a large number of different types of experiments and assays may be conducted including, for example, microarray analysis, encoded microparticle single and multiplex detection, tissue dissection and isolation, and other genetic analysis techniques. | 2012-06-21 |
| 20120157351 | COMPOSITION AND METHOD FOR REDUCING HYDRATE AGGLOMERATION - Disclosed and claimed is a composition and method of inhibiting the formation of hydrate agglomerates in a fluid comprising water, gas, and optionally liquid hydrocarbon comprising adding to the fluid an effective anti-agglomerant amount of the following formula and optionally salts thereof: | 2012-06-21 |
| 20120157352 | DEGRADABLE POLYMER COMPOSITIONS AND USES THEREOF - The invention relates to novel polymers derived from: (A) at least one N-vinyl amide-based unit and/or at least one acrylamide-based unit, and (B) at least one unit comprising: (i) at least one hydroxyl group, and/or (ii) at least one functional group convertible to a hydroxyl group wherein at least one group is converted to hydroxyl functionality in the final polymer product, wherein the polymer comprises at least one ester group. The polymers and compositions are used in oilfield applications, such as an inhibitor of gas hydrates and/or a kinetic inhibitor of gas hydrates. The polymer can assume alternating, block, and/or random configurations of the repeating units, with at least one ester group. | 2012-06-21 |
| 20120157353 | Water-Based Drilling Fluids Containing Crosslinked Polyacrylic Acid - A method of drilling a gas or oil well consists of use of a water-based drilling fluids containing high molecular weight crosslinked polyacrylic acid as viscosifying agent. The drilling fluid may further contain a lubricant, weighting agent and/or a wetting agent as well as laponite clay. The aqueous based drilling fluid exhibits a coefficient of friction which is substantially close to the coefficient of friction of oil based drilling muds. The drilling fluid exhibits stability at well temperatures in excess of 150° C. | 2012-06-21 |
| 20120157354 | FRICTION REDUCER - Disclosed herein is a composition comprising from about 0.1 wt % to about 50 wt % of a plant based product comprising mucilage. Methods of making the composition, a well treatment fluid comprising the composition, and methods of using the composition are also disclosed. | 2012-06-21 |
| 20120157355 | Phosphate Based Blend for Drilling and Completion Fluid - A drill-in and completion fluid for drilling through a producing zone in a subterranean formation or for completing a wellbore in a subterranean formation. The fluid comprises a blend of a phosphate brine and water. | 2012-06-21 |
| 20120157356 | Hydraulic fracturing with slick water from dry blends - A “slick water” fluid for hydraulic fracturing of wells is provided that is mixed by adding solid polymer and solid additives to water. The fluid may be batch mixed or mixed in a continuous process using standard blending equipment. Components are selected that are environmentally preferred. Lower cost and environmental benefits are realized. | 2012-06-21 |
| 20120157357 | DETERGENT PACKAGE FOR IMPROVED RECOVERY AND TRANSPORT OF CRUDE OIL - A detergent package for changing wettability of a hydrocarbon bearing formulation and method regarding the same, comprising, at least one surfactant selected from the group consisting of sodium dodecyl benzene sulfonate, sodium dodecyl sulfate and mixtures thereof, and additional components selected from the group consisting of corrosion inhibitors, alkaline agents, oxidizers, bleaches, secondary surfactants, divalent sequestering cations, foaming agents, inert additives and combinations thereof. | 2012-06-21 |
| 20120157358 | Self-Toughened High-Strength Proppant and Methods Of Making Same - Methods are described to make strong, tough, and lightweight whisker-reinforced glass-ceramic composites through a self-toughening structure generated by viscous reaction sintering of a complex mixture of oxides. The present invention further relates to strong, tough, and lightweight glass-ceramic composites that can be used as proppants and for other uses. | 2012-06-21 |
| 20120157359 | LUBRICATING OIL WITH IMPROVED WEAR PROPERTIES - Provided is a lubricating oil composition for internal combustion engines comprising at least one hydrocarbon base stock which is determined to exhibit a 40° C. PVC/100° C. PVC ratio approaching one or greater, and one or more lubricating additives. Also provided is a method for preparing such a composition, which includes determining the 40° C. PVC/100° C. PVC ratio of a hydrocarbon base stock oil, and selecting a hydrocarbon base stock oil which exhibits a 40° C. PVC/100° C. PVC ratio approaching one. One or more lubricating additives is then added to the selected base stock oil. | 2012-06-21 |
| 20120157360 | IONIC LIQUIDS HAVING HIGHER VISCOSITY - Method of adjusting the viscosity of a salt having a melting point of less than 100° C. at atmospheric pressure (referred to as ionic liquid for short), wherein a compound which has a content of at least 0.1 mol of functional groups/100 g of compound and in which the functional groups are selected from among acid, acid amide, amino, ammonium and hydroxyl groups is added to the ionic liquid. | 2012-06-21 |
| 20120157361 | LUBRICANT COMPOSITION - The lubricating oil composition of the invention includes a lubricating base oil with a kinematic viscosity at 100° C. of 1-6 mm | 2012-06-21 |
| 20120157362 | AZEOTROPIC AND AZEOTROPE-LIKE COMPOSITIONS OF METHYL PERFLUOROHEPTENE ETHERS AND HEPTANE AND USES THEREOF - The present disclosure provides azeotropic and azeotrope-like compositions comprised of methylperfluoroheptene ethers and heptane. The present disclosure also provides for methods of use for the azeotropic and azeotrope-like compositions. | 2012-06-21 |
| 20120157363 | AZEOTROPIC AND AZEOTROPE-LIKE COMPOSITIONS OF METHYL PERFLUOROHEPTENE ETHERS AND ETHANOL AND USES THEREOF - The present disclosure provides azeotropic and azeotrope-like compositions comprised of methylperfluoroheptene ethers and ethanol. The present disclosure also provides for methods of use for the azeotropic and azeotrope-like compositions. | 2012-06-21 |
| 20120157364 | Polymer Blends Useful as Viscosity Modifiers - The disclosed invention relates to a composition comprising an oil of lubricating viscosity, a hydrogenated copolymer of an olefin block and vinyl aromatic block, wherein the polymer is optionally functionalized, and a star polymer. Use of the composition as a lubricating composition is disclosed. | 2012-06-21 |
| 20120157365 | COMPOSITIONS COMPRISING POLYGLYCERYL NONIONIC SURFACTANTS - Provided are compositions comprising a polyglyceryl nonionic surfactant, a zwitterionic surfactant, an organic acid preservative, a non-sulfate anionic surfactant and water, wherein the composition is substantially free of ethoxylated materials and has a pH of about 5.4 or less, and uses thereof. Also provided are compositions comprising a polyglyceryl nonionic surfactant, a zwitterionic surfactant, an organic acid preservative, and water, wherein the composition is substantially free of ethoxylated materials, substantially free of sulfated anionic surfactants, and has a pH of about 5.4 or less, and uses thereof. | 2012-06-21 |
| 20120157366 | SKIN CLEANSING COMPOSITIONS WITH POLYGLYCEROL ESTERS AND HYDROPHOBICALLY MODIFIED POLYMERS - The methods and compositions of this invention relate to compositions containing polyglyceryl esters of fatty acids, low molecular weight hydrophobically-modified polymers and anionic and/or amphoteric surfactants having low irritation characteristics in combination with one or more additional characteristics, for example, relatively high clarity, relatively high foaming, and/or combinations thereof, as well as methods of making and using such compositions. These compositions have low pH values and are useful in cleansing the skin. | 2012-06-21 |
| 20120157367 | COMPOSITION AND METHOD FOR REMOVING PHOTORESIST AND BOTTOM ANTI-REFLECTIVE COATING FOR A SEMICONDUCTOR SUBSTRATE - A composition for removing photoresist and bottom anti-reflective coating from a semiconductor substrate is disclosed. The composition may comprise a nontoxic solvent, the nontoxic solvent having a flash point above 80 degrees Celsius and being capable of dissolving acrylic polymer and phenolic polymer. The composition may further comprise Tetramethylammonium Hydroxide (TMAH) mixed with the nontoxic solvent. | 2012-06-21 |
| 20120157368 | PROCESSING AGENT COMPOSITION FOR SEMICONDUCTOR SURFACE AND METHOD FOR PROCESSING SEMICONDUCTOR SURFACE USING SAME - The present invention is directed to provide a semiconductor surface treating agent composition which is capable of stripping an anti-reflection coating layer, a resist layer, and a cured resist layer in the production process of a semiconductor device and the like easily and in a short time, as well as a method for treating a semiconductor surface, comprising that the composition is used. The present invention relates to a semiconductor surface treating agent composition, comprising [I] a compound generating a fluorine ion in water, [II] a carbon radical generating agent, [III] water, [IV] an organic solvent, and [V] at least one kind of compound selected from a group consisting of hydroxylamine and a hydroxylamine derivative represented by the general formula [1], as well as a method for treating the semiconductor surface, comprising that the composition is used: | 2012-06-21 |
| 20120157369 | WASHING PERFORMANCE USING POLYMERS CONTAINING AROMATIC GROUPS - The present invention comprises polymers having optionally substituted aromatic residues in the polymer backbone and/or side chains, useful for the removal and/or dispersion of hydrophilic soils from textiles. The present invention also comprises a method for the removal of hydrophilic soils from textiles comprising the step of contacting the soil with a polymer that comprises optionally substituted aromatic residues in the backbone and/or side chains. The present inventive polymers and method are particularly useful in the context of washing or pretreatment agents that effectively remove red wine, fruit, vegetable, food product, or beverage stains from textiles. | 2012-06-21 |
| 20120157370 | WASHING PERFORMANCE USING RADICAL TRAPS - The invention relates to the use of radical traps in detergents and cleaners in order to improve cleaning performance, in particular for dirt containing polymerizable dyes. | 2012-06-21 |
| 20120157371 | HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2012-06-21 |
| 20120157372 | HUMAN MILK PEPTIDES - The present invention provides for novel peptides derived from human milk In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations. | 2012-06-21 |
| 20120157373 | ANTIMICROBIAL COMPOUNDS HAVING PROTECTIVE OR THERAPEUTIC LEAVING GROUPS - Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents. | 2012-06-21 |
| 20120157374 | NODULE SPECIFIC MEDICAGO PEPTIDES HAVING ANTIMICROBIAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINGING THE SAME - The present invention relates to the use of at least one peptide originated from | 2012-06-21 |
| 20120157375 | Identification of Inhibitors of a Bacterial Stress Response - A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription factor/sRNA pair (i.e., a transcription factor that regulates a sRNA). In particular, the present invention provides a system, a composition, a method and a kit for the identification of cyclic peptides that block the σ | 2012-06-21 |
| 20120157376 | PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHODS OF THEIR USE - This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections. | 2012-06-21 |
| 20120157377 | METHODS TO ENHANCE NIGHT VISION AND TREATMENT OF NIGHT BLINDNESS - The invention is for a safe and effective method of administering an opthalmological therapeutic agent for the treatment of night blindness and improving night vision, using insulin, and chlorin e6, preparations instilled into the conjunctival sac as ophthalmic drops. Night blindness and decreased night vision is associated with retinal diseases such as dry age related macular degeneration, retinitis pigmentosa and other such related eye diseases by using insulin, chlorin e6, ketamine, and monoclonal antibodies and IGF-1. The ophthalmic preparations may be supplemented with oral intake of various retinal photoreceptors vision supporting lutein, vitamin A, Zeaxanthin, Omega 3 Oils and other nurticeuticals. They may also be supplemented with cholesterol lowering statins in the elderly with high blood cholesterol to prevent eye diseases such as AMD contributing to night vision and night blindness. | 2012-06-21 |
| 20120157378 | Methods and Compositions for Predicting a Subject's Susceptibility To and Risk of Developing Type 2 Diabetes - Aspects of the invention include methods of predicting a subject's susceptibility to developing type 2 diabetes. Embodiments of the methods include obtaining a sex hormone-binding globulin (SHBG) level value for the subject, e.g., by detecting a SHBG plasma concentration and/or a SHBG polymorphism phenotype, and predicting the subject's susceptibility to developing type 2 diabetes from the obtained SHBG level value. Also provided are devices and kits that find use in practicing embodiments of the methods. In addition, methods of treating a subject for type 2 diabetes and/or preventing the onset of type 2 diabetes are provided. | 2012-06-21 |
| 20120157379 | Gastric Inhibitory Peptide Variants and Their Uses - Novel gastric inhibitory peptide (GIP) polypeptide compositions are provided. Human GIP alleles encode an extended peptide, referred to herein as GIP55S or GIP55G, which is resistant to serum degradation, relative to the known mature GIP peptide. GIP55S or GIP55G peptides find use where it is desirable to modulate insulin secretion. | 2012-06-21 |
| 20120157380 | PEGYLATED HUMAN APOA-1 AND PROCESS FOR PRODUCTION THEREOF - An isolated mono-pegylated apolipoproteinA-1, compositions comprising such, and methods of treating cardiovascular diseases using mono-pegylated apolipoproteinA-1 are provided as well as processes for making isolated mono-pegylated apolipoproteinA-1 and compositions containing such. | 2012-06-21 |
| 20120157381 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR - The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions. | 2012-06-21 |
| 20120157382 | PHARMACEUTICAL GLP-1 COMPOSITIONS HAVING AN IMPROVED RELEASE PROFILE - This invention relates to sustained release liquid pharmaceutical compositions containing a peptide analogue of glucagon-like peptide-1 or salts thereof having an improved release profile. The invention also relates to methods for preparing such compositions. | 2012-06-21 |
| 20120157383 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2012-06-21 |
| 20120157384 | MUTANTS PF4 POLYPEPTIDES EXHIBITING AN INCREASED ANTI-ANGIOGENIC ACTIVITY - The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein. | 2012-06-21 |
| 20120157385 | CYCLOSPORIN CONJUGATES - A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R | 2012-06-21 |
| 20120157386 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 2012-06-21 |
| 20120157387 | ORALLY BIOAVAILABLE D-GAMMA-GLUTAMYL-D-TRYPTOPHAN - Provided are compounds which are prodrugs of D-gamma-glutamyl-D-tryptophan, methods of making the compounds and methods for using the compounds. | 2012-06-21 |
| 20120157388 | EXTERNAL COMPOSITION FOR SKIN - A moisturizing agent comprising one or more than one compound selected from the group consisting of lysyl-β-alanine represented by the following general formula (1) and a salt thereof: | 2012-06-21 |
| 20120157389 | PEPTIDES FOR TREATING CANCER - The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX | 2012-06-21 |
| 20120157390 | IAP Inhibitors - Smac mimetics that inhibit IAPs. | 2012-06-21 |
| 20120157391 | PROTEOGLYCAN-CONTAINING MATERIAL - The present invention was made in view of an object to produce a novel proteoglycan-containing material, and find a novel use and/or a superior effect of the proteoglycan-containing material. The present invention provides a proteoglycan-containing material obtained from fish cartilage, wherein the proteoglycan-containing material comprises an acidic saccharide component having a molecular weight of not less than 2000 kDa. The proteoglycan-containing material provides advantageous effects for skin-moisturizing and skin anti-aging, including a superior skin fibroblast proliferation effect, an effect of enhancing and improving the skin barrier function, an effect of enhancing and improving the skin's capability to produce collagen, a dermis-thickening inhibition effect, and the like. | 2012-06-21 |
| 20120157392 | Epilepsy treatment employing ketogenic compounds which arrest apoptosis - Method of treating a patient suffering from apoptosis of tissue by administering to the patient a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced which arrests the apoptosis. | 2012-06-21 |
| 20120157393 | BIOPOLYMER, IMPLANT COMPRISING IT AND USES THEREOF - The present invention relates to a biopolymer, bioactive and totally biocompatible, very fluid at ambient temperature, capable of gelling in a sudden manner at 37° C., forming a solid implant, structurally integral and continuous having high mechanical properties. The biopolymer comprises at least a bioactive domain capable of directing in a precise manner the formation of a solid or semisolid implant. Furthermore the invention relates to any of the nucleic acids encoding the amino acid sequence of the biopolymer, implants, pharmaceutically acceptable vehicles, uses thereof, and a method of synthesis thereof. | 2012-06-21 |
| 20120157394 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF - The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided. | 2012-06-21 |
| 20120157395 | ANTI-INFLAMMATORY AGENT FOR ORAL APPLICATION, AND ANTI-INFLAMMATORY PEPTIDE FOR ORAL APPLICATION - Disclosed are a composition having an anti-inflammatory function and a therapeutic method using the composition, both of which are effective for inflammatory diseases such as inflammatory bowel disease. Specifically disclosed are: an anti-inflammatory functional agent for oral application, which comprises a soybean peptide, wherein the soybean peptide contains fractions each having a molecular weight of 500 or less and excluding any free amino acid in an amount of 40 wt % or more and has a free amino acid content of 7 wt % or less; and a therapeutic method using the anti-inflammatory functional agent. More specifically disclosed are: a novel tripeptide which comprises the following amino acid sequence: phenylalanine-leucine-valine or valine-proline-tyrosine and has an anti-inflammatory function; an anti-inflammatory composition for oral application, a medicinal agent and a feed, each of which contains the novel tripeptide as an active ingredient; and a method for treating inflammatory bowel disease using the novel peptide. | 2012-06-21 |
| 20120157396 | PYRAZINAMIDE FOR IMMUNOSTIMULATION AND THE TREATMENT OF LEISHMANIASES - Applicants claim the use of a pyrazine compound of formula I: | 2012-06-21 |
| 20120157397 | TRIMETHYLAMINE-CONTAINING COMPOUNDS FOR DIAGNOSIS AND PREDICTION OF DISEASE - The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases. | 2012-06-21 |
| 20120157398 | MATERIALS AND METHODS FOR TREATING DISEASES CAUSED BY GENETIC DISORDERS USING AMINOGLYCOSIDES AND DERIVATIVES THEREOF WHICH EXHIBIT LOW NEPHROTOXICITY - Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health. | 2012-06-21 |
| 20120157399 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES - Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes. | 2012-06-21 |
| 20120157400 | METHODS FOR TREATING KAPOSI SARCOMA - Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment. | 2012-06-21 |
| 20120157401 | METHODS FOR TREATING NEUROFIBROMATOSIS - Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment. | 2012-06-21 |
| 20120157402 | METHODS FOR TREATING BRAIN TUMORS - Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment. | 2012-06-21 |
| 20120157403 | BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS - Heterocyclic-substituted tricyclics of the formula | 2012-06-21 |
| 20120157404 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2012-06-21 |
| 20120157405 | Methods and Compositions for the Treatment of "Burning Feet Syndrome" - A composition for the treatment of “Burning Feet Syndrome” includes pantothenic acid or its analogs, or its derivatives, or its synonyms, alpha-lipoic acid or its analogs, or its derivatives, or its synonyms, and L-arginine or its analogs, or its derivatives, or its synonyms. The composition may also include at least one substance selected from the group consisting of B1, B2, B3, B6, B7, B9, B12, Acetly-L-Carnitine, N-acetlycystein, Omega-3 fatty acids, Omega-6 fatty acids, Vitamin E, and Taurine or any of their analogs, derivatives, or synonyms. The composition is used in a method for the treating of “Burning Feet Syndrome” by administering to a human such a composition. | 2012-06-21 |
| 20120157406 | METHOD OF PREVENTING DIARRHOEA - The present invention provides a method for the prevention of the incidence of and/or a reduction in the duration of acute diarrhoea, particularly in travellers, said method comprising orally administering an oligosaccharide composition, in particular a non-digestible oligosaccharide, to a mammal. | 2012-06-21 |
| 20120157407 | GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis. | 2012-06-21 |
| 20120157408 | MIXTURE OF HYALURONIC ACID FOR TREATING AND PREVENTING PEPTIC ULCER AND DUODENAL ULCER - The present invention is related to a method of treating and preventing peptic ulcer and duodenal ulcer by administering hyaluronic acid composition with a binary mixture of hyaluronic acids having mainly different weight-average molecular weight and then different rheological, scaffold and degradation properties in aqueous solution. The resulted compositions have demonstrated an optimal balance between adhesion, tissue scaffold and treating time to the peptic and duodenal ulcer and bleeding. Thus, the present inventive binary mixture exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding. | 2012-06-21 |
| 20120157409 | APPETITE SUPPRESSANT PRODUCT AND METHOD - An appetite suppressant composition that is effective for the control of mammalian weight and methods of administration of the composition of the invention are provided. The composition is a cellulose product prepared with ethanol preferably with added sweetener, spice(s), salt and protein for oral administration to a patient. | 2012-06-21 |
| 20120157410 | COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS - The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. | 2012-06-21 |
| 20120157411 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS - The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. | 2012-06-21 |
| 20120157412 | Substituted Pyrimidinyl Oxime Kinase Inhibitors - The present invention is directed to substituted pyrimidine compounds of formula (I): | 2012-06-21 |
| 20120157413 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 2012-06-21 |
| 20120157414 | CANNABINOID RECEPTOR ANTAGONISTS-INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers. | 2012-06-21 |
| 20120157415 | New Crystalline Form of Pemirolast - There is provided a hemihydrate form of the sodium salt of pemirolast. | 2012-06-21 |
| 20120157416 | XYLITOL CONTAINING COMESTIBLE PRODUCT - The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom. | 2012-06-21 |
| 20120157417 | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNO-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE - In one aspect, the present invention relates to amino-salicylic—aminophenylpropionic compounds for the use in the treatment of the inflammatory component of the celiac disease. These compounds act by blocking the cytokines released in the celiac disease and are specifically useful in the treatment of cases refractory to the diet, in dietary errors and in the reduction of the celiac disease remission time. | 2012-06-21 |
| 20120157418 | 2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D | 2012-06-21 |
| 20120157419 | METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE - The present invention relates to methods for treatment, prevention, and inhibition of progression of Alzheimer's disease, and other brain diseases characterized by amyloid plaque deposits, comprising the administration to a subject a bile acid fatty acid conjugates or bile salt fatty acid conjugate (FABAC). | 2012-06-21 |
| 20120157420 | TREATMENT AND PREVENTION OF SECONDARY INJURY AFTER TRAUMA OR DAMAGE TO THE CENTRAL NERVOUS SYSTEM - A method of administering one or multiple medications to human patients with CNS injury through oral or parenteral (including transdermal, intravenous, subcutaneous, intramuscular) routes. Inflammatory and immunological processes have been shown to cause secondary damage to CNS tissues in individuals with acute CNS injury. The present invention administers one or more of the following medications, which have properties that mitigate the inflammatory and immunological processes that lead to secondary CNS damage, via trans-dermal absorption: a statin compound (e.g., a HMG-CoA reductase inhibitor), a progesterone compound, or a cholinesterase inhibiting compound, among others, either alone or in combination with other compounds. | 2012-06-21 |
| 20120157421 | 17Beta-Alkyl-17Alpha-oxy-estratrienes - The invention relates to 17β-alkyl-17α-oxy-oestratrienes of the formula (I), to processes for their preparation, to the use of the 17β-alkyl-17α-oxy-oestratrienes for preparing pharmaceuticals and to pharmaceutical preparations comprising these compounds. | 2012-06-21 |
| 20120157422 | MARKER - The invention provides a method for identifying whether a pregnant subject has an increased risk of preterm labour comprising measuring the progesterone concentration in a sample obtained from the subject, wherein a reduced progesterone concentration is indicative of an increased risk of preterm labour and delivery. | 2012-06-21 |
| 20120157423 | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof - The present invention relates to a pharmaceutical composition in the form of a hydro-alcoholic gel or a solution for transdermal application, comprising:
| 2012-06-21 |
| 20120157424 | TREATMENT OF MENOPAUSE-ASSOCIATED SYMPTOMS - Described are estradiol-containing pharmaceutical compositions and, and methods using the same to alleviate menopause-related symptoms, such as hot flushes, by topically administering estradiol at low effective doses. | 2012-06-21 |
| 20120157425 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to new piperidine derivatives of the formula I | 2012-06-21 |
| 20120157426 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2012-06-21 |
| 20120157427 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 2012-06-21 |
| 20120157428 | BROMODOMAIN INHIBITORS AND USES THEREOF - The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. | 2012-06-21 |
| 20120157429 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2012-06-21 |
| 20120157430 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS - The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases. | 2012-06-21 |
| 20120157431 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators - A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders. | 2012-06-21 |
| 20120157432 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS - The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. | 2012-06-21 |
| 20120157433 | Heteroaryl Compounds as Kinase Inhibitors - The present invention provides a compound of Formula (I): | 2012-06-21 |
| 20120157434 | Antimicrobial heterocyclic compounds for treatment of bacterial infections - The present invention provides heterocyclic compounds of the following formula I: | 2012-06-21 |
| 20120157435 | Antiviral Compounds - Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and respiratory viruses including the common cold. | 2012-06-21 |
| 20120157436 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 2012-06-21 |
| 20120157437 | VLA-4 INHIBITORY DRUG - This invention relates to a VLA-4 inhibitory drug, having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally, wherein an active ingredient is represented by formula (I), or a salt thereof: | 2012-06-21 |
| 20120157438 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2012-06-21 |
| 20120157439 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 2012-06-21 |
| 20120157440 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: | 2012-06-21 |
| 20120157441 | INHIBITORS OF THE MUTANT FORM OF KIT - The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered. | 2012-06-21 |
| 20120157442 | HETEROARYL BTK INHIBITORS - The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same. | 2012-06-21 |
| 20120157443 | BRUTON'S TYROSINE KINASE INHIBITORS - The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same. | 2012-06-21 |
| 20120157444 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 2012-06-21 |
| 20120157445 | Cognitive Function - Provided herein are methods, drug formulations, and dosing regimens for improving cognitive function in a normal or cognitively impaired subject. For instance, methods provided herein comprise administering a GABA | 2012-06-21 |
| 20120157446 | MEDICAL USE - The present invention relates to a method for the treatment of urticaria which comprises administering to a patient in need thereof an effective amount of a compound which is 4-[(4-chlorophenyl)methyl]-2-({(2R)-1-[4-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl]oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1(2H)-phthalazinone, | 2012-06-21 |
| 20120157447 | Quinolone Carboxylic Acids, Derivatives Thereof, and Methods of Making and Using Same - A process of preparing a quinolone carboxylic acid or its derivatives having Formula I, Ia, or IV, as shown herein, comprises using a starting quinolone that already has one or more desired substituents at one or more particular positions on the quinolone ring and preserving the orientation of such substituents throughout the synthesis. The present process comprises fewer steps than prior-art processes. The present process also can include a simple separation of a desired enantiomer of the quinolone carboxylic acid or its derivatives from the enantiomeric mixture. Pharmaceutical compositions comprising fluoroquinolones prepared by the present process can be used effectively against a variety of microbial pathogens. | 2012-06-21 |
| 20120157448 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES - The invention provides novel tricyclic compounds of Formula I′ that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases. | 2012-06-21 |
